Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3Z-20-001
- Development stage
- Preclinical
- Lead developer
- 3Z Pharmaceuticals
- Modality
- Small Molecules
01
Overview
3Z-20-001 is a repurposed small molecule drug candidate being developed by 3Z Studio for the treatment of various neurological indications. It acts as an agonist at both the alpha-2 adrenergic receptor (α2) and the imidazoline I1 receptor. The drug was identified using 3Z Studio's proprietary zebrafish-based screening platform, which focuses on identifying CNS-active compounds through behavioral analysis. Preclinical proof-of-concept has been established in both zebrafish and rodent models. The development strategy for 3Z-20-001 leverages existing clinical data for a streamlined regulatory path, targeting a New Drug Application (NDA) in the United States and similar pathways in the European Union.
02
Targets
ADRA2A (α2A)I1R (Nischarin)
Beyond the preview
Go deeper on 3Z-20-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3Z-20-001.